Pipeline

Pipeline

The Potential to
Transform Treatment

Anokion is on the leading edge of harnessing the body’s natural immune tolerance pathway to address significant unmet medical need. Our innovative platform has the potential to treat multiple autoimmune diseases with therapies that deliver substantial clinical benefit without the untoward side effects associated with the current standard of care. Our goal is to discover, develop and deliver transformative therapies by directly and specifically modulating the patient’s own disease-associated T cells.

Discovery
IND-Enabling
Phase 1/2
Multiple Sclerosis

IND-Enabling / Clinical

ANK-101
Undisclosed

Candidate Selection